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During the last years, several studies have demonstrated that 
ras genes are involved in the signal transduction from transmem-
brane receptors to intracellular effectors, thus controlling cell
differentiation and growth (Marshall, 1996). Alteration of the
normal biologic function of ras proteins might be associated with
the acquisition of a neoplastic phenotype of cells (Lowy and
Willumsen, 1993). Mutational activation of ras oncogenes is
present in up to 90% of pancreatic cancers and 50% of all cases of
colorectal cancer (Bos, 1989), two neoplasms poorly responsive to
the treatment with traditional chemotherapeutic agents. Moreover,
the mutational activation of ras is associated with a poor prognosis
and a shorter survival of patients (Rodenhuis et al, 1997). Thus,
the inhibition of ras protein function could be an effective pharma-
cological approach in cancer chemotherapy.
Proteins belonging to the ras superfamily exert their functions
when they are localized to specific cellular compartments, and this
targeting is made possible by post-translational modifications
(Marshall, 1993). The first of them consists of the farnesylation of
the cysteine residue at the carboxyterminal tetrapeptide CAAX,
where C is cysteine, A any aliphatic amino acid, and X methionine
or serine (Maltese, 1990). This step is crucial, because its inhibi-
tion causes the interruption of the subsequent processing of the
cytosolic immature ras proteins, thus impairing their biological
functions (Gibbs, 1994). In this regard, numerous attempts have
been directed to the identification of chemotherapeutic agents
inhibitors of ras farnesylation (Tamanoi, 1993; Levitzky, 1996).
Among them, manumycin is a promising compound derived from
Streptomyces parvulus and characterized by Hara et al (1993).
Manumycin acts via the specific inhibition of the farnesyl:protein
transferase (FPTase), as demonstrated by the reversion of a 
ras-dependent phenotype in the worm Caenorhabditis elegans
(Hara and Han, 1995) and exerts antiproliferative effect on human
tumour cells which harbour a mutated K-ras gene (Nagase et al,
1996). However, the issue of therapeutic targeting of normal ras
proteins has not been addressed and data are lacking concerning
the ability of FPTase inhibitors to suppress the proliferation of
tumour cells with wild-type K-ras genes.
In the present work, the effect of manumycin was evaluated on
the processing of isoprenylated proteins of the ras superfamily, 
ras signal transduction pathway and cell death in the cell line
COLO320-DM derived from a human colorectal carcinoma.
METHODS
Drugs and chemicals
Antipain, leupeptin, aprotinin, sodium dodecyl sulphate (SDS) and
proteinase K were purchased from Boehringer Mannheim GmbH
(Mannheim, Germany). RPMI-1640 and fetal bovine serum (FBS)
were from HyClone (Cramlington, UK); L-glutamine, agarose and
180-bp DNA ladder were purchased from Gibco (Gaithersburg,
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DOI: 10.1054/ bjoc.1999.1018, available online at http://www.idealibrary.com on MD. USA) and acrylamide was from International
Biotechnologies Inc. (New Haven, CT, USA). Diethylamine
(DEA) and Nonidet P-40 were obtained from ICN Biomedicals
Inc. (Costa Mesa, CA, USA); mouse IgG1 anti-p21ras mono-
clonal antibody was purchased from Transduction Laboratories
(Lexington, KY), while anti-p21rap1, anti-p21rhoA and anti-
mitogen-activated protein kinase/extracellular-regulated kinase 
2 (p42MAPK/ERK2) rabbit polyclonal antibodies were from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Horseradish peroxidase-conjugated secondary antibodies (dilution
1:10 000) and reagents for chemiluminescent detection of protein
immunoblots were purchased from Amersham Life Science (ECL
Western detection kit, Little Chalfont, UK). All other chemicals
not listed in this section were from Sigma Chemical Co. (St Louis,
MO, USA).
Manumycin was a generous gift from Dr M Hara, Tokyo
Research Laboratories (Tokyo, Japan); the drug was dissolved in
sterile distilled water containing dimethyl sulphoxide (DMSO)
0.05% at 10-mM concentration, and stored at –20°C. Manumycin
and mevalonic acid (MVA) were diluted in sterile culture medium
immediately before their use.
Cell culture
The human colorectal cancer cell line COLO320-DM was obtained
from the American Type Culture Collection (ATCC, Rockville, 
MD, USA). COLO320-DM cells were maintained in RPMI-
1640 medium, supplemented with 10% FBS, penicillin 
(50 IU ml–1), streptomycin (50 mg ml–1) and L-glutamine (2 mM).
Cells were grown in 75-cm2 tissue culture flasks (Nunc, Roskilde,
Denmark) and kept in a humidified atmosphere of 5% carbon
dioxide (CO2) at 37°C. Cells were harvested with a solution of
trypsin–EDTA when they were in log phase of growth, and main-
tained at the above-described culture conditions for all experiments.
Polymerase chain reaction analysis of K-ras sequence
in COLO320-DM cell line
In order to demonstrate the possible mutations of K-ras sequence,
the mutational analysis of the codon 12 of the K-ras gene was
performed in COLO320-DM cells by oligodeoxynucleotide
hybridization, according to the method previously described
(Marchetti et al, 1996). As a negative control, the CLONE cell line
(ATCC, Rockville, MD, USA), derived from a normal human
corneal epithelium was analysed, while as a positive control a
sample of human lung adenocarcinoma with mutation at codon 12
(GGT ® TGT, Gly ® Cys) was used. The primers used to amplify
the K-ras gene around codon 12 were: 5¢-GGCCTGCTGAA-
AATGACTGA-3¢ and 5¢-TGATTCTGAATTAGCTGTAT-3¢. The
polymerase chain reaction (PCR) was programmed as follows:
initial denaturation, 4 min at 94°C; amplification, 30 s at 94°C, 30
s at 54°C and 1 min at 72°C for 35 cycles; elongation, 
10 min at 72°C. The amplified products of the PCR were dena-
tured, blotted onto nylon membranes and then hybridized with 32P-
labelled oligonucleotide probes specifically designed to detect ras
mutations (Marchetti et al, 1996).
Immunoblot analysis of p21ras, p21rap1, p21rhoA and
p42MAPK/ERK2
In order to document the farnesylation of p21ras and its associa-
tion with the cell membrane, COLO320-DM cells were exposed to
manumycin 1–10 mM for 24 h and membranes were separated
according to the method of Nagasu et al (1995), with minor
modifications. Briefly, cells exposed to manumycin and untreated
controls were harvested with ethylenediaminetetraacetic acid
(EDTA), washed three times with phosphate-buffered saline
(PBS), and centrifuged at 1000 rpm at 4°C for 5 min. Cells were
finally resuspended in 5 mM EDTA, 5 mM Tris-base (pH 7.6), 
1m M phenylmethylsulphonyl fluoride (PMSF), sonicated four
times for 10 s, and centrifuged at 12 000 rpm for 5 min at 4°C. The
supernatant was then centrifuged at 33 500 rpm for 30 min at 4°C,
and the resulting membrane pellet was solubilized in 0.01%
sodium dodecyl sulphate (SDS). Protein concentration of samples
was measured according to the method of Lowry et al (1951).
Proteins were then separated on 11% SDS-polyacrylamide elec-
trophoresis gel (SDS-PAGE), and transferred onto Immobilon-P
membrane (Millipore, Bedford, MA, USA) by using a Multiphor
II NovaBlot cell (Pharmacia, Uppsala, Sweden). Blots were
probed with an anti-p21ras antibody (1:1000) and detected with
the use of horseradish peroxidase-conjugated secondary antibody
(dilution, 1:10 000). The membranes were then exposed to a
Kodak X-Omat AR film, and film densities were quantified as
described in the section Analysis of Data.
In order to evaluate whether the reduction in membrane-bound
farnesylated p21ras is associated with the increase in the imma-
ture, non-farnesylated ras in the cytoplasm, total cellular extracts
were analysed for p21ras by immunoblotting. Briefly, cells
exposed to manumycin 1–10 mM for 24 h and untreated controls
were harvested with EDTA, washed three times with PBS and
centrifuged at 10 000 rpm for 5 min at 4°C. The cells were solubi-
lized at 4°C in Tris-base 50 mM pH 7.6, 2 mM EDTA, 100 mM
sodium chloride (NaCl), 1% Nonidet, 1 mM PMSF and 2 mg ml–1
each of aprotinin, pepstatin and antipain for 45 min. Cell lysate
was then centrifuged at 15 000 rpm for 20 min, and the pellet was
discarded. Aliquots of supernatants were used to measure protein
concentration as described above, and the remaining samples were
used for immunoblot assays. Samples were boiled for 5 min in
SDS-sample buffer (50 mM Tris-base pH 6.8, 2% SDS, 100 mM
dithiothreitol, 10% glycerol and 0.025% b-mercaptoethanol) 
and separated on 12.5% SDS-PAGE. Proteins were transferred
onto Immobilon-P membrane, probed with anti-p21ras antibody
(1:1000) and detected as described above.
To evaluate the effect of manumycin on protein geranylgeranyl-
ation and p42MAPK/ERK2 phosphorylation, COLO320-DM cells
were treated with manumycin 1–25 mM for 24 h. Cells were solu-
bilized in 1% Nonidet P-40, 50 mM Tris-base pH 7.6, 2 mM EDTA,
100 mM NaCl, 1 mM PMSF and 5 mg ml–1 each of antipain, apro-
tinin, pepstatin for 45 min at 4°C. In the case of p42MAPK/ERK2
analysis, the protein phosphatase inhibitors sodium metavanadate
and sodium fluoride (200 mM each) were added to the lysis buffer
(Danesi et al, 1995). Cellular lysates were centrifuged for 20 min
at 15 000 rpm, and aliquots of supernatants were separated to
measure protein concentration.
Total cellular proteins (100–200 mg) were boiled for 5 min in
SDS-sample buffer and separated on 11% (p42MAPK/ERK2) and
12.5% (p21rhoA and p21rap1) SDS-PAGE (Danesi et al, 1996).
Proteins were transferred onto Immobilon-P membrane and
probed with anti-p42MAPK/ERK2, anti-p21rhoA and anti-
p21rap1 antibodies (dilution, 1:1000), and detected as described
above.
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In order to document whether manumycin was able to affect
cholesterol synthesis, total cholesterol concentration was deter-
mined in 1.5 ´ 106 COLO320-DM cells treated with manumycin
1–10 mM for 24 h. Cells were harvested with trypsin-EDTA and
lysed in 55 ml of Tris-EDTA (TE) buffer (8 mM Tris-base pH 7.6,
0.5 mM EDTA pH 7.4) containing 0.5% Triton X-100 for 75 min 
at 4°C. Aliquots of suspensions were used to measure protein
concentration as described by Lowry et al (1951). Cholesterol was
assayed using the Cholesterol Detection Kit (Sigma Chemical Co.,
St Louis, MO, USA), based on cholesterol esterase/oxidase
enzymatic reactions, by measuring the absorbance at 500 nm of a
peroxidic dye product. Cholesterol levels were normalized to the
amount of protein in the sample and expressed as mg of cholesterol
mg–1 of protein.
Assay of apoptosis by manumycin
To demonstrate whether manumycin was able to trigger apoptosis,
COLO320-DM cells were treated with manumycin 1–25 mM for 
72 h, alone or in combination with MVA 100 mM. Cells were
harvested with trypsin–EDTA, and 3 ´ 106 cells for each sample
were centrifuged at 2600 rpm for 5 min and processed as previ-
ously reported (Danesi et al, 1995). Briefly, cells were lysed in 
TE buffer for 90 min at 4°C; cellular lysates were centrifuged at 
15 000 rpm for 1 h at 4°C, and clear supernatants containing
fragmented chromatin were digested at 42°C for 30 min with
proteinase K (200 mg ml–1). Samples were then diluted 1:1 in
phenol:chloroform:isoamyl alcohol, vigorously shaken for 30 s
and centrifuged at 15 000 rpm for 10 min.
Supernatants were collected and mixed with 100 ml of NaCl 
5 M, 1 ml of ethanol (4°C) and 1 ml of glycogen. The suspensions
were kept at –20°C overnight to precipitate DNA fragments, then
centrifuged at 15 000 rpm for 30 min; the supernatants were
discarded and the pellets were washed with 70% ethanol and dried
under air flow.
Each sample was resuspended in TE buffer containing 1 mg
ml–1 of boiled bovine pancreatic RNAase, incubated at 40°C for 
1 h and then mixed with DNA sample buffer (15 mM EDTA pH
8.0, 0.1% SDS, 0.025% xylene cyanole, 0.025% bromophenol
blue and 0.5% glycerol). Separation of DNA fragments 
was obtained by electrophoresis in 1% agarose gel, in
Tris–EDTA–acetate (TAE) buffer (Tris-base 32 mM, 1% glacial
acetic acid and 1 mM EDTA), and bands were visualized by
ethidium bromide staining under UV light. Gel was photographed
with a Polaroid MP4 Land camera (Polaroid, Cambridge, MA,
USA) and pictures were digitized for the analysis of DNA frag-
mentation as described in the section Analysis of Data.
Analysis of cytotoxicity
The effect of manumycin on COLO320-DM cell growth was eval-
uated on 1.5 ´ 106 cells well–1 seeded in flat-bottomed 6-well
plates (Nunk, Roskilde, Denmark), in a final volume of 1 ml
well–1, and incubated at 37°C in 5% CO2. At day 2, cells were
treated with manumycin 0.1–25 mM for 24 h, and then harvested
with trypsin–EDTA to measure their number. To assess the
possible effect of MVA on the antiproliferative activity of
manumycin, COLO320-DM cells were exposed for 24 h to
manumycin 0.1–25 mM in combination with MVA 100 mM, and
cell survival was calculated as described above. Proliferation of
treated cells was expressed as mean per cent values ± standard
error (s.e.) with respect to untreated controls.
Analysis of data
Film densities of protein immunoblots and apoptosis assays were
quantified through video imaging densitometry with the Kontron
Imaging system KS300 (Kontron Elektronic, Eching, Germany)
connected to a TK-1280E colour video camera (JVC, Tokyo,
Japan), and expressed as arbitrary units of mean grey values ± s.e.
(Danesi et al, 1996). The degree of apoptosis was assessed either
by single-band densitometric analysis of DNA fragments in the
range of 180–900 bp as well as by calculating the fragmentation
ratio (FR), as described by Kawabata et al (1994). Briefly, each
lane of agarose gels was divided into three areas: L area,
containing DNA fragments larger than 10 kbp; M area containing
DNA from 10 kbp to 0.3 kbp; and S area, the nucleosomal size
area, with DNA smaller than 0.18 kbp. The integration of the total
area of each lane (A) as well as M and S areas were IA, IM and IS,
respectively, and the FR was calculated as follows:
FR(%) = 100 ´ (0.5 ´ IM + 1 ´ IS)/IA
The analysis of the effects of manumycin on p21ras,
p42MAPK/ERK2 and cytotoxicity included the non-linear least
squares curve fitting of the experimental data in order to calculate
the drug concentration producing a 50% decrease in the optical
densities and cell proliferation (IC50). Results obtained from tripli-
cate experiments are given as mean values ± s.e. The two-tailed
unpaired Student’s t-test was used to assess the statistical differ-
ences of data obtained in control and treated cells with respect to
the analysis of protein immunoblots, cholesterol levels, extent of
apoptosis and cytotoxicity. P -values lower than 0.05 were consid-
ered significant.
RESULTS
Absence of K-ras gene mutation in COLO320-DM cell
line
The determination of point mutations at codon 12 of K-ras
oncogene was performed by PCR amplification of fragments
surrounding codon 12 of K-ras using genomic DNA as a template.
Amplified DNAs were hybridized with wild-type and mutation-
specific oligonucleotide probes. The analysis of DNA extracted
from COLO320-DM cells demonstrated indeed a normal K-ras
gene sequence while a GGT®TGT mutation was evident in one
allele of the lung tumour sample (Figure 1).
Inhibition of p21ras farnesylation and p42MAPK/ERK2
phosphorylation by manumycin
Immunoblots of COLO320-DM cell membranes or total cellular
lysates probed with anti-p21ras antibody revealed that manumycin
inhibited the post-translational processing of immature p21ras,
because increasing drug concentrations caused a proportional
decrease in the amount of farnesylated p21ras (Figure 2A and C).
Indeed, image analysis of signals obtained after Western blot 
assay of p21ras associated to cell membranes confirmed that
manumycin reduced the amount of membrane-bound protein
(Figure 2B), that is, the amount of farnesylated p21ras, and the
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farnesylation (2.68 ± 0.20 mM) was obtained by analysing the
amount of isoprenylated p21ras protein in total cellular extracts
(Figure 2D).
In addition to this, manumycin reduced the amount of the
active, phosphorylated form of p42MAPK/ERK2 (Figure 3A)
detected in total cellular extracts, the most important downstream
effector of ras. When the optical density ratio of phosphoryl-
ated/non-phosphorylated p42MAPK/ERK2 bands of treated cells
was analysed and compared to that of controls, it appeared that the
exposure to manumycin significantly decreased the amount of the
phosphorylated form of p42MAPK/ERK2, with a calculated IC50
of 2.40 ± 0.67 mM (Figure 3B).
Manumycin did not affect the geranylgeranylation of p21rap1
and p21rhoA (Figure 4), two members of the ras superfamily.
Indeed, the presence of an upper band of slower electrophoretic
motility, corresponding to the immature non-isoprenylated protein,
was not detected in Western blots of total cellular extracts probed
with the anti-p21rap1 and p21rhoA antibodies (Figure 4).
Absence of modification of cellular cholesterol by
manumycin
The analysis of cholesterol concentration in COLO320-DM cells
treated with manumycin 0.1–10 mM showed that the cholesterol:
protein ratio was unchanged in manumycin-treated cells with
respect to controls (Figure 5), providing further evidence that the
mechanism of action of manumycin did not involve the biosyn-
thesis of intermediates of the cholesterol biosynthetic pathway.
Indeed, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors, including lovastatin, decreased the overall
synthesis of final products derived from the isoprenoid bio-
synthetic pathway, including cholesterol, dolichol and ubiquinone
(Corsini et al, 1995).
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Figure 1 Determination of point mutations in codon 12 of the K-ras
oncogene by dot-blot hybridization analysis demonstrating that all samples
are positive for wild-type probe (GGT, Gly), while a TGT (Cys) mutation is
evident in one allele of the lung tumour sample. No K-ras mutations at codon
12 are present in the DNA of COLO320-DM cells
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Figure 2 Immunoblotting and image analysis of p21ras in samples of cellular membranes (A, B) and from total cellular lysates (C, D) of COLO320-DM cells
exposed to manumycin. Columns and bars, mean values ± s.e. respectively. F, farnesylated, N-F, non-farnesylated p21ras; *P < 0.05 vs controls
0               1              2              5              10
Manumycin (mM)
100
80
60
40
20
0
p
2
1 r a s
 
o
p
t
i
c
a
l
 
d
e
n
s
i
t
y
 
(
%
 
o
f
 
c
o
n
t
r
o
l
s
)
B
* *
*
*
0              1               2               5            10
Manumycin (mM)
100
75
50
25
0
p
2
1 r a s
 
o
p
t
i
c
a
l
 
d
e
n
s
i
t
y
 
(
%
 
o
f
 
c
o
n
t
r
o
l
s
)
D
Manumycin (mM)
0                 1                 2                 5              10
p21ras N-F
F {
CManumycin inhibits ras farnesylation in colon cancer cells 909
British Journal of Cancer (2000) 82(4), 905–912 © 2000 Cancer Research Campaign
Induction of apoptosis by manumycin in COLO320-DM
cells
Apoptosis was demonstrated by the occurrence of DNA digestion
into nucleosome-sized fragments, after extraction of DNA from
cells exposed to manumycin 1–25 mM alone or in combination
with MVA 100 mM (Figure 6). The extent of DNA fragmentation
was dependent on both the time of exposure (Figure 6, left) and the
concentration of the drug (Figure 6, middle). In particular, the
presence of chromatin fragments was not clearly detectable after
24 h of treatment, but when COLO320-DM cells were exposed to
the drug for longer times (48–72 h), DNA laddering became
evident (Figure 6, left and middle). DNA fragmentation occurred
in a dose-dependent manner in COLO320-DM cells treated with
manumycin for 72 h (Figure 6, middle) and was more evident as
compared to the shorter exposure. Quantitative image analysis of
DNA fragmentation confirmed that the increase in drug concentra-
tions was associated with enhanced optical density of DNA bands
corresponding to shorter fragments (180–900 bp) (Figure 7A),
whereas the fragmentation ratio of DNA extracted from treated
cells was not proportional to drug concentration (Figure 7B). MVA
was unable to reduce the apoptotic effect of manumycin (Figure 6,
right), as revealed by image analysis. Indeed, the presence of MVA
did not reduce the optical density of bands corresponding to
shorter fragments of DNA (Figure 7A) nor the fragmentation ratio
obtained with manumycin treatment (Figure 7B).
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Figure 3 Immunoblotting and image analysis of p42MAPK/ERK2 in
COLO320-DM cells treated with manumycin (A, B). Columns and bars, mean
values ± s.e. respectively. P, phosphorylated; N-P, non-phosphorylated
p42MAPK/ERK2 *P < 0.05 vs controls
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in COLO320-DM cells treated with manumycin
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treated with manumycin. Columns and bars, mean values ± s.e. respectively
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Inhibition of COLO320-DM cell proliferation by
manumycin
Manumycin reduced COLO320-DM cell proliferation in a dose-
dependent manner (Figure 8), and the calculated IC50 value was
3.58 ± 0.27 mM, in agreement with the results obtained in the
apoptosis assays. The cytotoxic activity of manumycin 0.1–25 mM
on COLO320-DM cell growth was not reduced by MVA 100 mM
(Figure 8), as demonstrated by an IC50 value (3.18 ± 0.19 mM) not
significantly different from that observed in the absence of MVA
(P > 0.05).
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Figure 8 Effect of manumycin alone or in combination with MVA 100 mM on COLO320-DM cell proliferation. Symbols and bars, mean values ± s.e. respectivelyDISCUSSION
Mutated  ras oncogenes are detected in human neoplasms,
including pancreatic cancer and colorectal neoplasms (K-ras) and
acute leukaemias (N-ras) (Bos, 1989). Moreover, the overexpres-
sion of ras oncogenes may be related to hormone-independent
growth (Danesi et al, 1996), neoangiogenesis and metastasis
(Larcher et al, 1996). All these biological characteristics contribute
to a poor clinical prognosis and reduced survival for patients.
Therefore, the aim of a number of studies was to identify new
agents able to disrupt the ras function (Tamanoi, 1993). Among
the new drugs, manumycin was first identified as an antimicrobial
agent exerting a specific inhibitory action on FPTase (Hara and
Han, 1995). In this view, the aim of this study was to evaluate the
effect of manumycin on the growth and ras protein isoprenylation
of a cell line derived from a human colorectal cancer expressing a
normal K-ras gene sequence.
The effect of manumycin in cells harbouring a mutated and acti-
vated ras oncogene has been documented (Nagase et al, 1996).
Therefore, the present study addressed the in vitro evaluation of
manumycin in cells characterized by the presence of a normal ras
gene as demonstrated by PCR analysis of K-ras sequence, in order
to investigate whether the cytotoxicity of a FPTase inhibitor is
limited to cells with a mutated ras gene or not. Indeed, the use of
FPTase inhibitors only in tumours with a mutation of ras gene may
be a limitation of their therapeutic usefulness since in a significant
number of solid tumours K-ras mutation may appear late in
tumour progression or does not occur.
Manumycin exerted a dose-dependent cytotoxic effect with 
an IC50 value very similar to that of isolated FPTase in vitro
(Tamanoi, 1993), and the inhibitory effect occurred at concentra-
tions lower than those of inhibitors of the synthesis of farnesyl or
geranylgeranyl moieties, including lovastatin (Corsini et al, 1995).
Furthermore, the present study demonstrates that MVA, from
which the isoprenyl donors farnesyl-pyrophosphate and geranyl-
geranyl-pyrophosphate are synthesized (Maltese, 1990), was not
able to reduce the cytotoxic effect of manumycin, suggesting that
the increased availability of isoprenoid moieties does not over-
come the inhibition of FPTase by manumycin.
It is interesting to note that the inhibitory effect of manumycin
on the HepG2 cell line, harbouring a mutated, activated ras onco-
gene (Nagase et al, 1996), occurred at higher concentrations than
those required for COLO320-DM, that expresses a normal K-ras
gene as reported in the present study. These discrepancies in
manumycin sensitivity among cell lines may be due to different
levels of expression or activity of ras, thus requiring a wide range
of manumycin concentrations to inhibit ras isoprenylation. The
data of the present study demonstrate that blocking the function of
a normal ras gene results in cell death, thus providing evidences
that cancer cells rely on the ras pathway whether the gene product
is normal or mutated.
The results from Western blot assays strenghtened the evidence
that the cytotoxic effect of manumycin could be dependent on the
inhibition of p21ras protein farnesylation. In addition to this, the
signal transduction from membrane receptors to downstream
effectors of p21ras was interrupted, as demonstrated by the
evaluation of p42MAPK/ERK2 activation. Indeed, COLO320-
DM cells, exposed to manumycin, showed a dose-dependent
decrease in the amount of activated, phosphorylated
p42MAPK/ERK2, a cytoplasmatic serine/threonine protein-kinase
that plays a fundamental role in the transduction of a number of
mitogenic signals, including growth factors (Marshall, 1995). In
particular, p42MAPK/ERK2 seems to be the major cytoplasmic
effector of p21ras-GTP activated complex, and the increase in the
phosphorylated, active form of p42MAPK/ERK2 is associated
with gene transcription and cellular proliferation (Marshall, 1996).
Therefore, the reduction of p21ras farnesylation caused a decrease
in p42MAPK/ERK2 activation, thus interfering with the signal
transduction from the cell membrane to the intracellular effectors
via the p21ras-p42MAPK/ERK2 pathway. The IC50 values of
p21ras and p42MAPK/ERK2 inhibition as well as the reduction of
cell viability appeared to be similar, providing evidence about the
dependence of one phenomenon from another.
In the present study, p21rhoA and p21rap1 were monitored 
to study whether protein geranylgeranylation was affected 
by manumycin or its effect was specific on farnesylation. These
proteins undergo geranylgeranylation by the geranylgeranyl:
protein transferase I; as a matter of fact, the results demonstrated
that their post-translational modification was not affected by
manumycin. The p21rhoA protein has a role in the regulation of
focal adhesion processes, differentiation and signal transduction
via integrins (Giancotti and Mainiero, 1994), while p21rap1
protein is physiological inhibitor of p21ras function (Ikeda et al,
1995; Nassar et al, 1995; Wittinghofer and Herrman, 1995).
Therefore, the prevalence of p21rap1 function over the inhibited
p21ras may be an additional factor contributing to the overall
activity of manumycin.
The importance of inhibition of Gy subunits and nuclear laminin
farnesylation (Giannakouros and Magee, 1993) by manumycin
cannot be underestimated, as well as the prenylation of other
proteins which required farnesyl moieties for their function (Cox
and Der, 1997). However, it appears that the inhibition of p21ras
farnesylation is a determinant factor in the antiproliferative effect
of manumycin on COLO320-DM cells. Apoptosis is an energy-
dependent process of cell death characterized by morphological
and biochemical alterations. One of the hallmarks of the apoptotic
death is the internucleosomal DNA fragmentation, with produc-
tion and release of oligonucleosomal size DNA fragments in 
the cytoplasm (Kawabata et al, 1994). The occurrence of this
phenomenon during treatment with isoprenylated inhibitors, 
like manumycin, is explained by the fact that many prenylated
proteins, including laminins A (Gibbs and Oliff, 1997), are
involved in the regulation and integrity of cell structures, such as
the nuclear envelope and lysosomes (Maltese, 1990; Perez-Sala
and Mollinedo, 1994), with possible loss of enzyme compartmen-
talization and DNA fragmentation (Danesi et al, 1996). It can be
concluded that the inhibition of FPTase activity by manumycin in
COLO320-DM cells is an important factor for DNA degradation.
Inhibitors of HMG-CoA, including lovastatin, prevent
isoprenylation by reducing the synthesis of farnesyl and geranyl-
geranyl moieties, but also the final products (cholesterol, dolichol,
ubiquinone) of MVA pathway (Corsini et al, 1995). Therefore, the
clinical use of statins may be characterized by the occurrence of
adverse effects, such as rhabdomiolysis and peripheral neuropathy
(Corsini et al, 1995; Phan et al, 1995; Veerkamp et al, 1996). On
the contrary, manumycin is a specific FPTase inhibitor that 
does not affect the biosynthesis of end products of isoprenoid
metabolism.
In conclusion, the results of the present study demonstrate that
manumycin is cytotoxic and induces apoptosis in a human cell line
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derived from a colorectal cancer which expresses a wild-type 
K-ras gene. This effect is obtained by inhibition of p21ras
farnesylation that reduces signal transduction through the p21ras-
p42MAPK/ERK2 pathway, without affecting protein geranyl-
geranylation or the synthesis of final products of the MVA
biosynthetic pathway.
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